Last reviewed · How we verify
NCT05393297: InGReS
InGReS: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study
NA trial testing Imaging: Intra-treatment FDG-PET-CT and MRI in Head and Neck Cancer in 15 participants. Status unknown.
16 June 2024
Quick facts
| Lead sponsor | Guy's and St Thomas' NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 17 June 2022 |
| Primary completion | 16 June 2024 |
| Estimated completion | 16 June 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Imaging: Intra-treatment FDG-PET-CT and MRI
- Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
Sponsor
Guy's and St Thomas' NHS Foundation Trust
Who can join
18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
InGReS is a phase I pilot study of adaptive dose-escalated radiotherapy in combination with platinum-based chemotherapy (CRT) for locally advanced head and neck cancer. InGReS will assess the feasibility of adapting the radiotherapy (RT) plan for each patient, based on anatomical and metabolic changes in the tumour seen on MRI and FDG-PET-CT performed after 2 weeks of CRT in a multicentre setting. The overall aim of the trial is to determine the safety and feasibility of delivering dose-escalated Intensity Modulated Radiotherapy (IMRT) to the residual primary tumour, as seen on intra-treatment imaging, in the final 3 weeks of RT.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05393297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other Guy's and St Thomas' NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07534917 — Comparing the Effects of Newer Pacemakers and Their Effects on the Heart and Valve Function in the Short-term. · not yet recruiting
- NCT07454135 — Mechanisms of Atrial Pathoelectrophysiology in HCM · not yet recruiting
- NCT07419945 — Older Kidney Patient Optimisation Pretransplant · NA · not yet recruiting
- NCT07309835 — Improving Genetic Medicine for Ethnic Minority Groups · not yet recruiting
- NCT07203872 — Inflammation-resolution Therapy in MINST of Periodontal Intrabony Defect: a Pilot Randomised Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05393297 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guy's and St Thomas' NHS Foundation Trust
- Last refreshed: 13 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05393297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing